Showing results (351-360 of 392) with videos related to

Sort By:
Pageof 40
American Heart Journal|June 15, 2018
Comparison of automated interval measurements by widely used algorithms in digital electrocardiographsPaul Kligfield, Fabio Badilini, Isabelle Denjoy, et al.
Inflammatory Bowel Diseases|February 14, 2019
Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort StudyLoes H C Nissen, Lauranne A A P Derikx, Anouk M E Jacobs, et al.
The American Journal of Surgical Pathology|July 9, 2019
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 ResultsSuzanne C van Es, Bert van der Vegt, Frederike Bensch, et al.
Investigational New Drugs|January 10, 2018
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancerDiane A J van der Biessen, Jourik A Gietema, Maja J A de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerUdai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Oral Oncology|June 19, 2018
Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glandsE Boon, M H Valstar, W T A van der Graaf, et al.
Oncotarget|October 9, 2015
Better survival of renal cell carcinoma in patients with inflammatory bowel diseaseLauranne A A P Derikx, Loes H C Nissen, Joost P H Drenth, et al.
Molecular Oncology|July 28, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancerErik J van Helden, Lindsay Angus, C Willemien Menke-van der Houven van Oordt, et al.
International Journal of Cancer|August 30, 2008
Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activationCarla M L van Herpen, Robbert van der Voort, Jeroen A W M van der Laak, et al.
NPJ Precision Oncology|November 6, 2022
Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patientsTessa J J de Bitter, Philip R de Reuver, Elise A J de Savornin Lohman, et al.
Pageof 40